Evaluation of Teratogenic Activity of Antiepileptic Drug Lamotrigine in Mouse Fetuses by Mobini, G et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/333356848
Evaluation of Teratogenic Activity of Antiepileptic Drug Lamotrigine in Mouse
Fetuses
Article  in  Folia medica · May 2019
DOI: 10.3897/folmed.61.e34916
CITATIONS
0
READS
30
4 authors, including:
Some of the authors of this publication are also working on these related projects:
Bio compatibility test of materials View project
Colorectal cancer, microRNA View project
gholam reza reza Mobini
Tehran University of Medical Sciences
13 PUBLICATIONS   73 CITATIONS   
SEE PROFILE
Abbas Karimi
Tabriz University of Medical Sciences
17 PUBLICATIONS   78 CITATIONS   
SEE PROFILE
Abolfazl Akbari
Iran University of Medical Sciences
41 PUBLICATIONS   172 CITATIONS   
SEE PROFILE
All content following this page was uploaded by Abbas Karimi on 24 May 2019.
The user has requested enhancement of the downloaded file.
77
Folia Medica 61(1): 77–82
DOI: 10.3897/folmed.61.e34916
Copyright Akinnuga AM et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Evaluation of Teratogenic Activity of 
Antiepileptic Drug Lamotrigine in Mouse 
Fetuses
Gholam Reza Mobini1,2, Abbas Karimi3, Abolfazl Akbari4, Forouzan Rahmani5
1 Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 Department of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
4 Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran
5 Department of Anatomy, Shahrekord Faculty of Medicine, University of Medical Sciences, Shahrekord, Iran
Corresponding author: Forouzan Rahmani, Department of Anatomy, Shahrekord Faculty of Medicine, University of Medical Sciences, Kashani St., 
88157-13471 Shahrekord, Iran; E-mail: forahmani@yahoo.com; Tel: +983833349113
Received: 28 Nov 2017 ♦ Accepted: 27 Sept 2018 ♦ Published Online: 24 Oct 2018 ♦ Published: 31 March 2019
Citation: Mobini GR, Karimi A, Akbari A, Rahmani F. Evaluation of teratogenic activity of antiepileptic drug lamotrigine in mouse 
fetuses. Folia Med (Plovdiv) 2019; 61(1):77-82. doi: 10.3897/folmed.61.e34916
Abstract
Background: Use of antiepileptic drugs during pregnancy can be associated with an increased risk of teratogenicity as well as con-
genital abnormalities. However, there are numerous discrepancies to determine whether lamotrigine, as an antiepileptic drug, can 
significantly induce malformation in newborn infants or not. Thus, the purpose of the study was to evaluate the teratogenic effects of 
lamotri-gine on mouse fetuses.
Materials and methods: In the present study, 21 pregnant mice were assigned to four groups. Groups 1 and 2 (controls) received 
mock treatment and ethanol 20%, respectively. Groups 3 and 4 (treatment) were intraperitoneally administered with 25 and 75 mg/kg 
lamotrigine for three days, respectively. The treatment protocol was performed within the gestational days of 9-18 in all groups. On ges-
tational day 18, 117 fetuses were taken out of the fallopian tube of studied mice and then examined for any anomalies (vertebral, limbs 
and cranial), followed by a measurement of their height and weight.
Results: The results revealed that, in the treated groups, the weight and the height had significantly decreased (p<0.01) and also vari-
ous anomalies were evident. Moreover, as the dose of lamotrigine increased, the decrease in the weight and the height and rising trend 
in anomalies were intensified.
Conclusion: According to the findings, lamotrigine (LTG) could be considered as a risk factor for the development of the anomalies 
examined.
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BACKGROUND
Birth defects, congenital deformities, congenital anomalies, 
as well as congenital abnormalities are terms similarly re-
ferred to deficiencies in structure, function, and metabo-
lism leading to physical and mental disabilities or death.1 
Genetic and environmental factors as well as their potential 
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interactions involved in pathogenesis include single gene 
disorders, chromosomal abnormalities, maternal medical 
conditions, and exposure to environmental toxins, sub-
stance abuse, infections, drugs, chemicals, radiations, and 
hyperthermia. The mechanical constraints on fetal2 and an-
tiepileptic drugs (AEDs) have been reported to affect fetal 
development throughout pregnancy and also increase the 
risk of major congenital abnormalities in the neonates3,4.
According to previous reports, traditional antiepileptic 
drugs such as phenobarbital, phenytoin, carbamezapine, 
and valproate can increase the risk of congenital malforma-
tions in pregnant women.3,5 Generally, AEDs are classified 
into two groups according to their risks for pregnancy. The 
first group consists of a number of conventional drugs that 
have been extensively investigated for teratogenic effects. 
The second group, as the newer AEDs, has not been con-
firmed in terms of their teratological effects.6,9 In general, 
LTG can have an acceptable safety profile and it can be used 
as an effective medication in the treatment of epilepsy and 
various cognitive disorders.10,11 For example, C9H7Cl2N5 is 
a phenyltriazine derivative that is rapidly and completely 
absorbed after oral administration.12,13 This drug can also 
act by inhibiting the release of glutamate in voltage-depen-
dent sodium channels.
There are few studies regarding the emergence of 
LTG-induced teratogenic anomalies in pregnancy and 
epilepsy.3,14 Moreover, there are several methodological 
challenges concerning such investigations. For example, a 
small sample size inadequately demonstrates possible tera-
togenic effects of AEDs, namely lamotrigine. Furthermore, 
comprehensive interpretations of teratological data have 
not been evaluated in previous studies. Nevertheless, some 
research on animals have shown that oral administration 
of LTG in mice and rats induces no teratogenic effects, but 
it can increase preterm birth and fetal death.14 In another 
study by Bastaki et al.15, LTG at 25-300 mg/kg in pregnant 
mice was reported to initiate muscle contraction, weight 
loss, preterm birth, as well as craniofacial deformities such 
as cleft palate and exencephaly. However, no vertebral and 
limb anomalies were reported. In the brain of rat fetuses 
receiving lamotrigine, a reduced body weight at birth could 
increase the volume and the diameter of the cerebral struc-
ture whilst augmented density of subcortical layer and ven-
tricle dilatation was reported.16 No study has been inclusi-
vely conducted to examine the teratogenic effects of LTG 
in humans and most investigations have shed light on LTG 
in combination with other drugs. Therefore, the observed 
fetal complications could not be attributed merely to LTG. 
So far, a few research studies have been conducted to explo-
re the physiological mechanisms of LTG and its potential 
therapeutic applications in mice models of epilepsy17,19 but 
there are limited studies on LTG teratogenicity. Additio-
nally, most studies have considered oral intake of the drug. 
Therefore, the purpose of this study was to investigate the 
in vivo teratogenic effects of intraperitoneal administrati-
on of LTG on mice fetuses. Such studies could help further 
understand the negative effects of teratogenes in terms of 
preventing the potential side effects on pregnant women 
and fetuses.
MATERIALS AND METHODS
This experimental study was conducted on 21 pregnant 
mice (Pasteur Institute, Tehran, Iran). The use of animals 
in this experiment was approved by the Research Commit-
tee affiliated to Department of Anatomy, School of Health, 
Shahrekord University of Medical Sciences, under the gui-
delines of the National Advisory Committee for Laboratory 
Animal Research20 and National Institute of Health for the 
use of laboratory animals.21 After the animals were trans-
ferred to the School of Medicine at Shahrekord University 
of Medical Sciences, they were allowed to adapt themsel-
ves to the new environment at 21±1°C and 12 h light/dark 
cycle. Then, three or four female mice were kept with one 
male mouse in a cage for breeding. The next morning, the 
mice were examined for vaginal plug and the ones with a 
vaginal plug were isolated. To closely determine the onset 
of pregnancy, the researchers separated male and female 
mice again and the day the vaginal plug was noted was con-
sidered as day 0 of pregnancy.
It should be noted that pure LTG powder (Hetero Drugs 
Limited, India) is slightly soluble in water, so LTG was dis-
solved in ethanol.22 Ethanol 20% (Merck, Germany) mo-
dified with 1 ml distilled water was used for LTG adminis-
tration. Since ethanol by itself is a potential confounding 
factor, a control group (control 2) was considered which 
was administered with ethanol alone.
It has been established that LTG at a dose of 25 mg/kg 
can act as a teratogen and it can also lead to the death of 
mice at doses higher than 75 mg/g.18 Therefore, a dose ran-
ge of 25-75 mg/kg was considered for the present study. The 
pregnant mice were then assigned to four groups; group 1 
(control one; 32 offspring obtained) received no treatment, 
group 2 (control two; 31 offspring obtained) was intraperi-
toneally administered with 1 ml ethanol three times a day 
(every 8 hours) from the gestational day 9, and groups 3 
(treatment one; 36 offspring obtained) and 4 (treatment 
two; 18 offspring obtained) were intraperitoneally admi-
nistered with LTG at 25 and 75 mg/kg doses, respectively.
On gestational day 18, all the mice were anesthetized 
and killed through cervical dislocation. Then, the embryos 
were taken out of the fallopian tube by opening an anteri-
or abdominal wall and separately examined for superficial 
morphology, as well as vertebral, limb, and cranial anoma-
lies upon the removal of fetal membranes. Three types of 
anomalies consisting of vertebral (scoliosis and kyphosis), 
limb (amelia and micromelia), and cranial (exencephaly 
and anencephaly) were evaluated and the incidence rates 
of resulting complications for the four studied groups were 
compared. The weight of fetuses was then measured using 
a digital weight (Sartorius) to the nearest 0.01 g and their 
height (crown-rump length) was measured using a caliper 
to the nearest 0.1 mm. The obtained data were analyzed by 
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Kruskal-Wallis H test and Chi-square test using SPSS Sta-
tistics (Version 22) and levels of significance were conside-
red by <0.05.
RESULTS
The findings of the study are summarized in Table 1. Figs 
1 and 2 also illustrate some emerged anomalies in the for-
mation of fetal extremities. Based on the findings, ethanol 
caused a decrease in weight and height. Once LTG was 
introduced, a significant descending trend in weight and 
height was also observed, that was further increased by ad-
ding the dose (p<0.001). The incidence rates of anomalies 
among the four groups were also compared in Table 1. In 
groups 3 and 4, the incidence rates of anomalies increased 
as the dose of LTG was administered. Table 2 shows the 
number and percentage of observed skeletal anomalies in 
mouse fetuses in the four study groups. Anomalies were 
observed in the sham group (receiving only the solvent) 
and treatment groups but the difference between the sham 
group and treatment groups was reported to be significant 
(p< 0.05). Notably, 5 min after administration of LTG at 
75 mg/kg, myoclonic contractions were initiated and con-
tinued for 2 to 3 minutes. During pregnancy, following the 
administration of lamotrigine, 1 and 3 deaths in the 25 and 
75 mg/kg groups were observed, respectively.
DISCUSSION
Treatment of epilepsy in pregnant women can be consis-
tently associated with many complications, so fetuses expo-
sed to AEDs are more predisposed to various problems.15,23 
Lamotrigine, one of the novel anti-epileptic medications, 
is widely used either alone or in combination with other 
medications for treating epileptic seizures in adults and 
children. There is also enough evidence showing that LTG 
passes through the placenta easily and is secreted in the 
breasts.24 Moreover, LTG is classified as a group C drug and 
its use is limited to the treatment of various types of epile-
psy according to Food and Drug Administration.24 Howe-
ver, since this medication can contribute to the treatment 
of other chronic neurological diseases including bipolar 
disorder and migraine with aura, trigeminal syndrome is 
increasing.11,25,26 Given that the available data regarding 
teratogenic effects of LTG are scarce, previous studies have 
mostly considered oral intake of this drug.3,27 Furthermo-
re, it is increasingly being taken for the treatment of many 
neurological diseases. Thus, the purpose of this study was 
to investigate the in vivo teratogenic effects of LTG on mice 
fetuses.
The study of superficial characteristics and anomalies in 
the fetuses of the mice administered with LTG have indica-
ted some variations in the course of growth and develop-
ment as well as morphogenesis of these fetuses (Table 1). 
Table 1. Comparison of height, weight, and anomalies in mice fetuses among different groups. p-values indicate comparison between 
treatment groups (receiving 25 and 75 mg/kg lamotrigine) and control 2 (sham) group
Study group Control 
(n=32)
Sham 
(n=31)
Treatment 1 
(n=36)
P-value Treatment 2
(n=18)
p-value
Variable
Median weight (g) 1.38 0.99 0.865 <0.001 0.84 <0.001
Median height (mm) 2.615 2.04 2 <0.05 1.795 <0.001
Rate of anomalies (%) 0.0% 16.1% 50% <0.001 52.8% <0.001
Table 2. Frequency and percentage of observed skeletal anomalies in mice fetuses of four study groups
Study group Control* 
(n=32)
Sham# 
(n=31)
Treatment 1 
(n=36)
P-value Treatment 2
(n=18)
p-value
Variable
Scoliosis 0 2 (6.5 %) 13(36.1%) <0.001 7(38.9%) < 0.001
Costal fusion 0 5 (16.1 %) 11(30.6%) <0.05 6(33.3%) <0.05
Bifurcation 0 4 (12.9%) 11(30.6%) <0.05 6(33.3%) <0.05
*Mice in the control group did not receive anything.
#Mice in the sham group received only the solvent.
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As shown in Table 1, there was a significant difference in 
terms of height and weight among the four study groups. 
In group 2, a decrease in weight and height after admi-
nistrating ethanol as a LTG solvent was seen compared to 
group 1.
Consistent with previous investigations,7,15,28 the fin-
dings of the present study indicated that the height and the 
weight of the fetuses had significantly decreased once LTG 
had been administrated in a dose-dependent manner (Ta-
ble 1).
Decreased height and weight could be due to a variety 
of reasons, but researchers generally argued that the use of 
AEDs during pregnancy could cause decreases in total pro-
tein content within the fetuses and consequently a decline 
in height and weight.27 Obviously, LTG during pregnancy 
could be considered as a risk factor for fetal growth and 
development whilst potentially causing reductions in the 
weight and height of the fetuses. The obvious anomalies in 
the present study included scoliosis and kyphosis (in ver-
tebrae), amelia and micromelia (in limbs), as well as unen-
cephaly and exencephaly (in cranium). Based on the fin-
dings of this investigation, various anomalies increased in 
group 2 in comparison with group 1, but the incidence rate 
of anomalies significantly increased with the addition of 
LTG in a dose-dependent manner in groups 3 and 4. The-
re are also several discrepancies among previous reports in 
terms of determining whether LTG has teratogenic effects 
in human fetuses of not.
The results of previous studies have indicated that oral 
intake of LTG in mice and rats at doses 1.2 times higher 
than the one used by humans (500 mg/kg) can be asso-
ciated with no anomalies but could lead to preterm birth 
and decreased fetal weight.14,27 However, Bastaki et al. and 
Padmanabhan et al. found that intraperitoneal administra-
tion of LTG, at doses above 75 mg/kg, could result in cra-
niofacial anomalies such as cleft palate, exencephaly, and 
caudal.15,29
LTG can easily pass through the placenta and therefore 
affect fetal development and lead to anomalies.30 The me-
chanism through which LTG causes anomalies remains to 
be adequately explained. It is believed that this drug de-
creases fetal folate levels that would be a main factor con-
tributing to the development of congenital anomalies in 
humans.29,31 
Essentially, because of these reasons, daily intake of 5 mg 
folic acid alongside AEDs, including LTG, in the first tri-
mester helps to considerably decrease teratogenic effects.32 
Other evidence has indicated that the inclusion of serum 
levels methionine and free radicals produced by AEDs may 
be involved in the emergence of congenital anomalies in 
the fetus of pregnant women with epilepsy being treated 
with this drug.6,7,15
CONCLUSIONS
In conclusion, the use of LTG during pregnancy throug-
hout organogenesis could have potential teratogenic effects 
and disturb fetal growth and development. In this study, 
ethanol as a substance with well-known teratogenic ac-
tion was used for dissolving lamotrigine. Since the final 
concentration of injected ethanol for each mouse was less 
than 2%, less adverse effects of emerging anomalies were 
experienced; so the obtained results should be interpreted 
with caution. According to these results, lamotrigine could 
be considered as a risk factor for the development of ano-
malies. The potentially decreased serum concentrations 
of folate and methionine could contribute to induce these 
anomalies. Therefore, more studies are needed to further 
investigate the effects of this medication and explain the 
relevant mechanisms.
Figure 1. Anomalies in the formation of fetal extremities in the 
embryo administered with lamotrigine at 25 mg/kg.
Figure 2. Kyphosis and aplasia of the right upper limb in the 
embryo administered with lamotrigine at 75 mg/kg.
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Резюме
Введение: Приём антиэпилептических препаратов во время беременности может быть связан с повышенным риском 
тератогенности, а также врождённых аномалий. Тем не менее, существует много противоречивых мнений о том, может 
ли ламотриджин, как противоэпилептическое лекарственное средство, в значительной степени индуцировать пороки 
развития у новорожденных или нет. Таким образом, целью исследования является установление тератогенного воздействия 
ламотриджина на эмбрион мыши.
Материалы и методы: В настоящем исследовании 21 беременная мышь были распределены в 4 группы. Группы 1 и 2 
(контрольные) были подвергнуты фиктивной обработке и 20% этанолу соответственно. Группы 3 и 4 (проходившие лечение) 
получали 25 и 75 мг / кг в течение 3 дней. Протокол лечения был выполнен в рамках 9-18 гестационного дня для всех групп. 
На 18-й день беременности 117 эмбрионов были удалены из маточных труб исследованных мышей и затем исследованы на 
наличие аномалий (позвоночника, конечностей и черепной коробки) с последующим измерением их роста и веса.
Результаты: Результаты показали, что в обработанных группах вес и рост были значительно снижены (р <0,01) и установлено 
наличие различных аномалий. Кроме того, с увеличением дозы ламотриджина нарастали снижение веса, роста и тенденция 
к росту количества аномалий.
Заключение: Согласно полученным данным, ламотриджин можно рассматривать как фактор риска развития исследованных 
аномалий.
Ключевые слова: 
антиконвульсанты, врождённые аномалии, мышь, ламотриджин, тератогены
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